|
|
T2 Biosystems to Unveil New Data at September Conferences
|
|
|
T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Mu B.1.621 and Iota B.1.526 Variants of the SARS-CoV-2 Virus
|
|
|
T2 Biosystems Announces Plans to Consolidate and Expand Facilities in Massachusetts
|
|
|
T2 Biosystems Recognizes Sepsis Awareness Month with Thought Leadership Campaign and Participation in Sepsis Alliance Health Equity Pledge
|
|
|
T2 Biosystems Announces Second Quarter 2021 Financial Results
|
|
|
T2 Biosystems to Participate in the Canaccord Genuity 41st Annual Growth Conference
|
|
|
T2 Biosystems to Report Second Quarter 2021 Financial Results on August 5, 2021
|
|
|
T2 Biosystems Reports Granting of Inducement Award
|
|
|
T2 Biosystems to Participate at Clinical Conferences in June and July 2021
|
|
|
World’s Leading Proxy Advisory Firms ISS and Glass Lewis Recommend T2 Biosystems Stockholders Vote “FOR” the Charter Amendment Proposal – To Increase the Number of Authorized Shares of Common Stock
|
